Смертельно опасные лекарства и организованная преступность

43. Lieberman J. A., Stroup T. S., McEvoy, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209–23.

44. Jones P. B., Barnes T. R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63: 1079–87.

45. Woo W. W. K., Man S.-Y., Lam P. K. W., et al. Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinfl ammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med. 2005; 46: 352–61.

46. Villanueva P., Peiry S., Librero J., et al. Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003; 361: 27–32.

47. Wilkes M. S., Doblin B. H., Shapiro M. F. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.

48. Jørgensen A. W., Hilden J., Gøtzsche P. C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006; 333: 782–5.

49. Malhotra D. Pharmaceutical lies. BMJ. 2006 Oct 28.

50. Spurling G. K., Mansfield P. R., Montgomery B. D., et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010; 7: e1000352.

51. Bowman M. A., Pearle D. L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.

52. Bowman M. A. The impact of drug company funding on the content of continuing medical education. Mubius. 1986; 6: 66–9.

53. Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).

54. Tramur M. R., Reynolds D. J., Moore R. A., et al. Impact of covert duplicate publication on metaanalysis: a case study. BMJ. 1997; 315: 635–40.

55. Aspinall R. L., Goodman N. W. Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ. 1995; 311: 844–6.

56. Carlisle J., Stevenson C. A. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006; 3: CD004125.

57. Carlisle J. B. A meta-analysis of prevention of postoperative nausea and vomiting: randomized controlled trials by Fujii et al. compared with other authors. Anaesthesia. 2012; 67: 1076–90.

58. Does anesthesiology have a problem? Final version of report suggests Fujii will take retraction record, with 172. Retraction Watch. 2012 July 3.

59. Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.

60. Studdert D. M., Mello M. M., Brennan T. A. Financial confl icts of interest in physicians’ relationships with the pharmaceutical industry – self-regulation in the shadow of federal prosecution. N Engl J Med. 2004; 351: 1891–900.

61. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

62. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.

63. Heissel A. [‘The bomb’ has been defused]. Dagens Medicin. 2011 Feb 4.

64. Graudal N., Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010; 62: 2852–63.

65. Tanne J. H. FDA approves prostate cancer ‘vaccine’ treatment. BMJ. 2012; 340: 998.

66. Hodi F. S., O’Day S. J., McDermott D. F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–23.

67. Andersen N. V. [Drug with trivial effect]. Politiken. 2012 Feb 5.

68. Rasmussen L. I. [‘How can Henrik Dibbern believe that I have interests in the company?’] Ugeskr Læger. 2012; 174: 248–9.

69. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.